

BAB BIO VENTURES NV  
Form 3/A  
January 28, 2005

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|  |   |  |   |   |   |
|--|---|--|---|---|---|
| <p>1. Name and Address of Reporting Person *</p> <p>MPM BIO VENTURES I LLC</p> <p>(Last) (First) (Middle)</p> <p>C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE, 31ST FLOOR</p> <p>(Street)</p> <p>BOSTON, MA 02199</p> <p>(City) (State) (Zip)</p> | <p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>01/19/2005</p> | <p>3. Issuer Name and Ticker or Trading Symbol</p> <p>VIACELL INC [VIAC]</p> | <p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p><input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner<br/><input type="checkbox"/> Officer <input type="checkbox"/> Other<br/>(give title below) (specify below)</p> | <p>5. If Amendment, Date Original Filed(Month/Day/Year)</p> <p>01/19/2005</p> | <p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input type="checkbox"/> Form filed by One Reporting Person<br/><input checked="" type="checkbox"/> Form filed by More than One Reporting Person</p> |
|--|---|--|---|---|---|

**Table I - Non-Derivative Securities Beneficially Owned**

| 1. Title of Security<br>(Instr. 4) | 2. Amount of Securities Beneficially Owned<br>(Instr. 4) | 3. Ownership Form:<br>Direct (D)<br>or Indirect (I)<br>(Instr. 5) | 4. Nature of Indirect Beneficial Ownership<br>(Instr. 5) |
|------------------------------------|--|---|--|
|------------------------------------|--|---|--|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security<br>(Instr. 4) | 2. Date Exercisable and Expiration Date<br>(Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security<br>(Instr. 4) | 4. Conversion or Exercise Price of | 5. Ownership Form of Derivative | 6. Nature of Indirect Beneficial Ownership<br>(Instr. 5) |
|---|---|--|------------------------------------|---------------------------------|--|
|---|---|--|------------------------------------|---------------------------------|--|

Edgar Filing: BAB BIO VENTURES NV - Form 3/A

|                          | Date Exercisable | Expiration Date | Title        | Amount or Number of Shares | Derivative Security | Security: Direct (D) or Indirect (I) (Instr. 5) |                  |
|--------------------------|------------------|-----------------|--------------|----------------------------|---------------------|---|------------------|
| Common Stock Warrant     | Â (1)            | 11/12/2007      | Common Stock | 333,333                    | \$ 1.5              | I   | See Footnote (2) |
| Common Stock Warrant     | Â (1)            | 05/21/2009      | Common Stock | 100,000                    | \$ 1.5              | I   | See Footnote (2) |
| Series D Preferred Stock | Â (3)            | Â (3)           | Common Stock | 666,667                    | \$ 0 (3)            | I   | See Footnote (2) |
| Series E Preferred Stock | Â (3)            | Â (3)           | Common Stock | 1,666,667                  | \$ 0 (3)            | I   | See Footnote (2) |
| Series G Preferred Stock | Â (3)            | Â (3)           | Common Stock | 2,000,000                  | \$ 0 (3)            | I   | See Footnote (4) |
| Series H Preferred Stock | Â (3)            | Â (3)           | Common Stock | 470,155                    | \$ 0 (3)            | I   | See Footnote (5) |
| Series I Preferred Stock | Â (3)            | Â (3)           | Common Stock | 194,128                    | \$ 0 (3)            | I   | See Footnote (7) |
| Series J Preferred Stock | Â (3)            | Â (3)           | Common Stock | 125,000                    | \$ 0 (3)            | I   | See Footnote (6) |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| MPM BIO VENTURES I LLC<br>C/O MPM ASSET MANAGEMENT<br>111 HUNTINGTON AVENUE, 31ST FLOOR<br>BOSTON,Â MAÂ 02199 | Â             | Â X       | Â       | Â     |
| BB BIOVENTURES L P<br>C/O MPM ASSET MANAGEMENT<br>111 HUNTINGTON AVENUE, 31ST FLOOR<br>BOSTON,Â MAÂ 02199     | Â             | Â X       | Â       | Â     |
| BAB BIO VENTURES LLP<br>C/O MPM ASSET MANAGEMENT<br>111 HUNTINGTON AVENUE, 31ST FLOOR<br>BOSTON,Â MAÂ 02199   | Â             | Â X       | Â       | Â     |
| BAB BIO VENTURES NV<br>C/O MPM ASSET MANAGEMENT<br>111 HUNTINGTON AVENUE, 31ST FLOOR<br>BOSTON,Â MAÂ 02199    | Â             | Â X       | Â       | Â     |
| MPM ASSET MANAGEMENT INVESTORS 2000A LLC<br>C/O MPM ASSET MANAGEMENT  | Â             | Â X       | Â       | Â     |

111 HUNTINGTON AVENUE, 31ST FLOOR  
BOSTON, MA 02199

MPM BIO VENTURES PARALLEL FUND L P  
C/O MPM ASSET MANAGEMENT  
111 HUNTINGTON AVENUE, 31ST FLOOR  
BOSTON, MA 02199

^ ^ X ^ ^

MPM BIO VENTURES I LP  
C/O MPM ASSET MANAGEMENT  
111 HUNTINGTON AVENUE, 31ST FLOOR  
BOSTON, MA 02199

^ ^ X ^ ^

## Signatures

|   |            |
|---|------------|
| By Luke Evnin, manager of MPM BioVentures I LLC /s/ Luke Evnin  | 01/28/2005 |
| **Signature of Reporting Person   | Date       |
| By Ansbert Gadicke, managing director of BAB BioVentures, N.V., the general partner of BAB BioVentures L.P., the general partner of BB BioVentures L.P. /s/ Ansbert Gadicke | 01/28/2005 |
| **Signature of Reporting Person   | Date       |
| By Ansbert Gadicke, managing director of BAB BioVentures, N.V., the general partner of BAB BioVentures L.P. /s/ Ansbert Gadicke   | 01/28/2005 |
| **Signature of Reporting Person   | Date       |
| By Ansbert Gadicke, managing director of BAB BioVentures NV /s/ Ansbert Gadicke   | 01/28/2005 |
| **Signature of Reporting Person   | Date       |
| By Luke Evnin, manager of MPM Asset Management Investors 2000A LLC /s/ Luke Evnin   | 01/28/2005 |
| **Signature of Reporting Person   | Date       |
| By Luke Evnin, manager of MPM BioVentures I LLC, the general partner of MPM BioVentures I L.P., the general partner of MPM BioVentures Parallel Fund, L.P. /s/ Luke Evnin   | 01/28/2005 |
| **Signature of Reporting Person   | Date       |
| By Luke Evnin, manager of MPM BioVentures I LLC, the general partner of MPM BioVentures I L.P. /s/ Luke Evnin   | 01/28/2005 |
| **Signature of Reporting Person   | Date       |

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Immediately exercisable.
- (2) The securities are held by BB BioVentures L.P.
- (3) Each share of Preferred Stock will convert automatically on a 1 for 1 basis into shares of Common Stock upon the closing of Issuer's initial public offering.
- (4) The shares are held as follows: 1,720,000 by BB BioVentures, L.P. ("BB BioVentures"), 260,600 by MPM BioVentures Parallel Fund, L.P. ("MPM Parallel") and 19,400 by MPM Asset Management Investors 2000A LLC ("MPM Asset"). BB BioVentures is under common control with MPM Parallel. BAB BioVentures L.P. ("BAB BV"), BAB BioVentures NV and MPM BioVentures I LLC ("BioVentures LLC") are the direct and indirect general partners of BB BioVentures. MPM BioVentures I L.P. ("BioVentures LP") and BioVentures LLC are the direct and indirect general partners of MPM Parallel. The Reporting person is a manager of MPM Investors, BioVentures LLC and MPM Asset. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his

Edgar Filing: BAB BIO VENTURES NV - Form 3/A

pecuniary interest therein.

- (5) The shares are held as follows: 404,334 by BB BioVentures, 61,261 by MPM Parallel and 4,560 by MPM Asset.
- (6) The shares are held as follows: 111,167 by BB BioVentures, 12,620 by MPM Parallel and 1,213 by MPM Asset.

The shares are held as follows: 130,880 by MPM BioVentures II-QP, L.P. ("BV II QP"), 14,444 by MPM BioVentures II, L.P. ("BV II"), 2,715 by MPM Asset Management Investors 2001 LLC ("AM 2001") and 46,089 by MPM BioVentures GmbH & Co.

- (7) Parallel-Beteiligungs KG ("BV KG"). MPM Asset Management II, L.P. ("AM II GP") and MPM Asset Management II LLC ("AM II LLC") are the direct and indirect general partners of BV II QP, BV II and BV KG. The Reporting Person is a member of AM 2001 and AM II LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Â

**Remarks:**

ThisÂ amendmentÂ isÂ beingÂ filedÂ solelyÂ toÂ includeÂ MPMÂ AssetÂ ManagementÂ InvestorsÂ 2000AÂ LLCÂ which ofÂ filing.Â Â SeeÂ FormÂ 3Â filedÂ forÂ MPMÂ BioVenturesÂ IIÂ LLCÂ forÂ additionalÂ membersÂ ofÂ theÂ jointÂ

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.